Divis Laboratories Q2 FY27 Earnings Call: PAT Jumps 64%, CDMO Growth Hits 50% (DIVISLAB)

Divis Laboratories Ltd held its Q2 FY27 earnings call on November 07, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Quarter with Broad-Based Profit Growth

• Q2 FY 2026-2027 total income of Rs.3,770 crores — up ~32% YoY from Rs.2,860 crores in Q2 FY 2025-2026; PBT of Rs.1,505 crores (+65%) and PAT of Rs.1,127 crores (~64% growth).
• H1 FY 2026-2027 total income of Rs.6,907 crores — vs Rs.5,389 crores in H1 FY 2025-2026; H1 PAT of Rs.2,029 crores, up 64% YoY.
• H1 CC standalone revenue growth of 17% — exports ~90% of standalone sales, with Europe + North America together ~75%; generics 38% vs custom synthesis 62% of H1 FY 2026-2027 sales.
• Net material consumption improved to ~32% of sales in H1 FY 2026-2027 from 40% in H1 FY 2025-2026, attributed to higher CS mix and heavy backward integration at Unit 3 Kakinada.
• Net forex gain of Rs.20 crores in H1 FY 2026-2027 — down from a Rs.103 crores gain in H1 FY 2025-2026.
• Cash flow from operations (pre-tax) declined 50% to Rs.959 crores in H1 FY 2026-2027 — despite PBT growing 50-60%; management attributed the gap to the ongoing large capex cycle rather than working capital lock-up.

Validation Batches Power ~50% CDMO Growth; Commercialization Near

• CDMO business grew ~50% YoY in Q2 FY 2026-2027 — following ~40% in Q1 FY 2026-2027 (per analyst framing, not disputed by management); growth attributed to execution of validation batches for certain projects.
• 3 major dedicated capital investment programs are in validation stages as of Q2 FY 2026-2027; one is very close to commercialization, with the other two expected to reach commercialization over Q3-Q4 FY 2026-2027, after which facilities will be fully utilized since they house product-specific equipment.
• Regulatory approval timing remains undetermined — Dr. Kiran Divi said the agency would grant approval either based on past history or via a pre-approval inspection; no notice had been received on either front as of the call, and management did not address whether commercial batch margins will match validation batch margins.
• ~60-70 projects handled at any given time — spanning pre-chemistry, pre-qualification and qualification stages, including phase 2 and phase 3 molecules; management declined to break out the count currently in validation/qualification.
• Sacubitril-valsartan LOE risk flagged — the analyst noted the top CDMO product faces genericization with LOE in November 2026 (FY 2026-2027); management declined to comment, citing confidentiality of CDMO projects.
• No semaglutide generic play confirmed — Dr. Kiran Divi stated there is no semaglutide opportunity on the generic side as of now; only already-declared generics (naproxen, gabapentin) are open for discussion.

Integrated Peptide Ambition, But Capacity Details Withheld

• Several 3,000-liter SPPS reactors being installed as of Q2 FY 2026-2027 — added for project-specific customer validations; new lines are being cautiously installed based on customer programs spanning GLP-1s and multiple other therapeutic categories.
• Backward integration to basic raw materials — Dr. Kiran Divi reiterated the ambition to be the largest integrated peptide player, with resins, protected amino acids and tags all manufactured in-house; the in-house vs bought-in split was not disclosed as the peptide business sits under CDMO.
• No SPPS capacity quantification or timeline — asked whether capacity could scale to a multiple of the installed base by ~FY 2029-2030, management gave no timeline and declined to quantify against the analyst's floated ~50,000 KL range, stating only that with futuristic capacity Divi's will be among the top 3 players (period unspecified).
• Commercial purification deferred — the company has an integrated peptide center of excellence capable of gram-scale purification and will look at commercial purification only as and when customers move toward commercialization; Dr. Kiran Divi declined to comment on whether purification/isolation could bottleneck global peptide programs.
• Route and technology choice is customer-dictated — SPPS process approach (batch vs flow chemistry) and reactor sizing "depend on the contract"; peptide work is strictly for innovator programs with no generic peptides made currently.
• 20-year peptide heritage cited — Divi's has historically been a key supplier of peptide building blocks; liquid-phase synthesis strength means no dedicated liquid-phase capacity program, with regular reactors providing effectively unlimited small-volume capacity.

Management Holds 32-35% Margin Guidance Despite 40%+ H1

• Second consecutive quarter of 40%+ EBITDA margin — taking H1 FY 2026-2027 EBITDA margin to almost 40%; Neelima Prasad Divi did not raise the earlier FY 2026-2027 guidance of 32-35%, saying consistency at current levels is "what we all wish for" but stopping short of any commitment.
• FY 2026-2027 revenue guidance reiterated at double-digit growth — management declined to specify whether it would be 10% or 20%, against the 17% CC growth actually delivered in H1 FY 2026-2027.
• Finished goods and WIP inventory built up by Rs.1,197 crores in H1 FY 2026-2027 — majority attributed to volume of material stocked at various stages to ensure on-time delivery; management could not comment on how much relates to dedicated projects awaiting customer approval, and no offtake commitment or take-or-pay detail was provided.
• Three months of critical raw material cover stocked — due to Middle East geopolitical issues; some critical raw material prices have escalated, and supply risks include volatile petrochemical-based solvent costs, Red Sea/Suez Canal routing delays and higher ocean and air freight.
• Generics stable but pricing pressure persists — healthy volume growth across segments, with pricing pressures in certain product categories the key risk; management focused on competitiveness, manufacturing efficiencies and disciplined capacity utilization.

Rs.2,000 Crore Annual Run-Rate; No Capacity Shortage Foreseen

• Annual capex of Rs.2,000 crores ±20% indicated for FY 2027-2028 to FY 2029-2030 — to be looked at year-on-year, based on the RFP pipeline and the company's matched strengths; management declined to allocate future capacity between GLP-1 peptides, non-GLP-1 peptides, small molecules or other verticals.
• Rs.772 crores of assets capitalized in Q2 FY 2026-2027 — taking H1 FY 2026-2027 capitalization to Rs.1,223 crores; CWIP of Rs.1,638 crores as of September 30, 2026; management said it remains "prudent and conscious" about capex spend.
• Heavy backward integration investment at Kakinada — creating additional capacity for certain critical raw materials and freeing up space at existing facilities; spend is divided uniformly across Units 1/2/3, with active spending on flow chemistry and new-generation quality control equipment.
• No capacity shortage currently or foreseen — responding to analyst Neha Manpuria's question on ~85-90% utilization (her recollection from Q2 FY 2026-2027) and post-FY 2029-2030 risk, Dr. Kiran Divi said additions are planned well in advance with customers, and long-term CS contracts provide visibility into utilization requirements.
• Capacity base: Unit 1 has ~22 production blocks, Unit 2 has 25 and Unit 3 has 6 — only 3 production blocks across all units are dedicated; the remaining plants are multi-purpose and quickly changeable.
• Proactive shell-capacity strategy — Dr. Kiran Divi clarified Divi's builds blocks without investing in equipment upfront; investment begins as molecules progress from phase 3 to pre-validation to commercial.

Growth Opportunities Broad, But Key Questions Left Open

• Nutraceuticals revenue of Rs.571 crores in H1 FY 2026-2027 — vs Rs.492 crores in H1 FY 2025-2026; management cited increasing global emphasis on preventive healthcare, wellness and scientifically validated ingredients as a growth opportunity.
• Every segment growing on its own — asked for a 3-year view on peptides, contrast media and generics, Dr. Divi said small molecules, peptides, nutraceuticals and generics are all growing, with generics seeing good volume/usage growth despite pricing pressure; no quantified segment-level guidance was offered.
• No CDMO run-rate guidance into H2 FY 2026-2027 — management said it is "very difficult" to quantify whether the Q2 validation-driven pace continues, given multiple projects in the pipeline; validation batches typically carry significantly higher margins than the base business and may not recur.
• Bonus issue query deferred to the board — Neelima Prasad Divi stated a bonus share decision rests with the board and any information would come "as and when the time is right"; no timeline or indication of intent was provided.
• Company-wide asset turnover of ~1.5x as of Q2 FY 2026-2027 — management declined to disclose asset turns for the peptide vertical specifically or compare peptide vs small-molecule turns within custom synthesis.
• CSR footprint — the safe drinking water initiative provides clean drinking water to more than 13 lakh individuals every day as of Q2 FY 2026-2027.